UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/806,689	07/13/2001	Boris Tartakovsky	TARTAKOVSKY I	5905

1444 7590 11/17/2004

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON, DC 20001-5303

EXAMINER	
EWOLDT, GERALD R	

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 11/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/806,689	TARTAKOVSKY ET AL.	
	Examiner	Art Unit	
	G. R. Ewoldt, Ph.D.	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *09 September 2004*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-22* is/are pending in the application.

4a) Of the above claim(s) *1-7,18-20 and 22* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *8-17 and 21* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☒ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

1. Claims 8-17 and 21 are pending and under examination.

2. In view of the instant amendment and response, filed 9/09/04, the previous rejections under the second paragraph of 35 U.S.C. 112 have been withdrawn.

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 8-17 and 21 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, for the reasons of record set forth in the action mailed 4/09/04. Specifically, the specification provides insufficient evidence that the claimed method could be used to identify individuals with a high probability of having an infection or monitor the efficacy of a treatment.

As set forth previously, It is noted that given the language of the instant claims the claimed invention is intended to encompass significant breadth, i.e., methods of monitoring *any and all* types of infection, including but not limited to, bacterial, viral, fungal, and parasitic infections. For the invention to function then, it would be required that it be established that increased CD14 be present in the T cells of individuals suffering from *any and all* types of infections. Additionally, for the claimed method of monitoring the efficacy of a treatment to be enabled, it would be necessary that the specification establish that CD14 levels are reduced in response to efficacious treatment. Accordingly, it appears then that, given their novelty and considering their breadth, the enablement of the claimed methods would require a significant disclosure representative of all of the infections and all of the treatments encompassed by the claims. Said disclosure would most obviously take the form of the measurement of CD14 in T cells in a representative number of infectious models or infection types, accompanied by the measure of the reduction of CD14 in T cells

after a representative number of treatments of said infections. Additionally, other limitations (as discussed below) would also require enablement.

A review of the specification discloses just three relevant examples (4, 5, and 6), the data from which are set forth in Tables 1 and 2 and Figures 10, 11, and 12. Example 4 (Figures 10, 11, and 12) asserts that some individuals suffering from bacterial sepsis and HIV infection display increased MO2 in CD3+ cells. However, the figure legends disclose only "various kinds of infections" while Figures 10 and 12 themselves discloses only "infectious diseases" and Figure 11 itself discloses only "individuals". It is thus impossible to evaluate whether or not the diseases and subjects of the example are representative of those encompassed by the claims. In fact, the example and figures are essentially impossible to interpret given the lack of specific information disclosed in them. Example 5 (Table 1) discloses that MO2 is seen at higher levels in γ/δ T cells. It is unclear how this information could relate to the infected or treated individuals of the claims. Example 6 (Table 2) discloses that asymptomatic HIV+ patients show more MO2 in their T cells. Table 3 shows that 2 of 4 treated HIV+ patients showed a decrease in MO2 while 2 of 4 treated patients did not. In total then, it appears that the examples demonstrate only that: 1) MO2 may be increased in the T cells of HIV+ patients, and 2) that decrease in MO2 levels cannot be used as an accurate or reliable measure of the efficacy of treatment in HIV+ patients. This limited disclosure cannot be considered to be representative (nor enabling) of the scope of the claims.

Regarding additional limitations not enabled by the specification, there is no showing that the MO2 antigen is ever "expressed" by T cells. Indeed, the Inventors' own work (Tartakovsky et al., *Immunol. Letts.*, 2003) teaches that the protein is most likely not expressed at all by T cells, but rather it is internalized from an external source. Regarding the limitations of Claims 10-12 and 15-17 regarding the types of T cells employed in the comparisons to healthy cell populations, the specification discloses only that HIV+ CD8+ T cells show increased MO2 levels. In the case of CD4+ T cells, again only HIV+ cells are employed and in this instance the standard deviations approach (or exceed) the percentage of positive cells. Regarding γ/δ T cells, there is no disclosure comparing healthy to infected cells with any infectious agent.

Applicant's arguments, filed 9/09/04, have been fully considered but they are not persuasive. Applicant asserts that the specification shows sufficient results to enable the invention as claimed.

Applicant has not addressed each of the arguments/grounds of rejection set forth by the Examiner above. Thus, for the reasons set forth above, it remains the Examiner's position that the limited disclosure of the specification is insufficient support for the methods of the instant claims.

5. No claim is allowed.

6. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

8. **Please Note**: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Additionally, the Technology Center receptionist can be reached at (571) 272-1600.

G.R. Ewoldt, Ph.D.
Primary Examiner
Technology Center 1600

11/12/04

G.R. EWOLDT, PH.D.
PRIMARY EXAMINER